Clinical Trials Directory

This study is for people with type 1 diabetes (T1D). Their immune system attacks cells in the body that make insulin. A new treatment called GNTI-122 is made from their own blood cells and may help stop this attack. People will be in one of three groups: low dose, high dose, or high dose with another medicine called rapamycin. The study includes several visits to check if the treatment works and is safe.

This study includes several steps and lasts about 208 days in total. It begins with a screening period that lasts 28 days. During this time, you will have a full physical exam, your medical history will be reviewed, and you will have routine lab tests, a heart test called an electrocardiogram, and a sensor placed to check your blood sugar levels. If you qualify and choose to join, you will be randomly assigned on the first dose day to receive either the study drug, called CNP-103, or a placebo, which does not contain any active medicine. The medicine or placebo will be given through a vein. The treatment period lasts 90 days, followed by another 90 days of follow-up. During this time, doctors will check how your body reacts to the medicine and how safe it is.

If you choose to join this study, you will complete up to 10 study visits and 2 phone call check-ins over 72 weeks. This study includes:

• Pulmonary function tests (how well your lungs are working)
• CT scans of the chest (a special type of imaging that creates 3D X-ray images)
• Blood draws
• Questionnaires

We are building a database of people who would like to be contacted about future dermatology research studies. This is a way for people who are interested in participating in research opportunities to learn about a research study that they may not have otherwise known about.

We are doing this study to test the safety and effectiveness of the study drug, datopotamab deruxtecan (also known as dato-DXd), and find out if it is a potential option for patients with metastatic breast cancer that has spread to the brain and/or spinal cord.

We are doing this study to find out if an experimental vaccine called Cov-RBD-scNP-001 (the study vaccine) provides safe and effective protection against multiple different coronaviruses, including the virus that causes COVID-19. We want to know the effects of the vaccine when it's given at 3 different dose levels.

We are doing this study to find out if an investigational drug called iptacopan (the study drug) is safe and has beneficial effects for people who have generalized Myasthenia Gravis (gMG).

This study will last about 35 weeks and has three parts: Screening, Dosing, and Follow-up. It is a double-blind study, which means neither you nor the doctors will know if you get the real medicine or a placebo. The medicine or placebo will be given as two shots under the skin. After you agree to join, treatment will start. There will be phone calls at weeks 3, 5, 7, 9, and 11 to check on your medicine and any side effects. You will have regular health checkups, physical exams, and tests like ECGs to check your heart. You will also answer short surveys about your symptoms, energy, mood, and work. You will come back at 3, 6, and 12 months for blood tests. Over the whole study, about one cup of blood will be taken. These tests will check your health, medicine levels, antibodies, and screen for diseases like HIV, hepatitis, and tuberculosis.